BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 4,940 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 4,940 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40. Following the transaction, the chief executive officer owned 1,120 shares of the company’s stock, valued at approximately $303,027.20. This represents a 81.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $263.61 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a fifty day moving average price of $301.03 and a 200 day moving average price of $315.60. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The firm has a market cap of $28.92 billion, a price-to-earnings ratio of 58.97 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion during the quarter. As a group, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on ONC shares. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. Leerink Partners increased their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Royal Bank Of Canada raised their target price on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Wells Fargo & Company started coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price for the company. Finally, Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their target price for the stock from $420.00 to $290.00 in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $390.00.

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently modified their holdings of ONC. Cetera Investment Advisers bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $455,000. Rhumbline Advisers bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $275,000. Arrowstreet Capital Limited Partnership purchased a new position in BeOne Medicines during the 2nd quarter valued at about $505,000. Invesco Ltd. purchased a new position in BeOne Medicines during the 2nd quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $68,000. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.